Trilinolein [537-40-6]

Minimum order 2

Referência HY-128393-1mL

Tamanho : 10mM/1mL

Marca : MedChemExpress

Contactar o distribuidor local :


Telefone : +1 850 650 7790

Description

Trilinolein is an orally active triglyceride that inhibits the PI3K/Akt, Ras/MEK/ERK signaling pathways, and MMP-2. Trilinolein can reduce oxidative stress, induce apoptosis, and inhibit cell migration. Trilinolein can be used in the research fields of cardiovascular disease, cerebrovascular disease (such as cerebral ischemia), and non-small cell lung cancer[1][2][3].

IC50 & Target

MMP-2

 

In Vitro

Trilinolein (10 μM; 24 h) can increase the cell viability of endothelial cells stimulated by ox-LDL (HY-NP135), reduce apoptosis, inhibit ICAM-1 and E-selectin mRNA expression, and enhance antioxidant activity (increased SOD and GPX, decreased MDA)[1].
Trilinolein (3.12-100 μg/mL; 24-48 h) inhibits the viability of A549, A498 and MKN-45 cells, induces apoptosis and G0/G1 phase arrest in A549 cells, downregulates the PI3K/Akt pathway, and increases intracellular ROS[2].
Trilinolein (5-20 μM; 24-72 h) inhibits PDGF-BB-stimulated A7r5 vascular smooth muscle cell migration and reduces the protein levels of Ras, MEK, p-MEK, p-ERK, and MMP-2[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Apoptosis Analysis[1][2]

Cell Line: Endothelial cells; A549 cells
Concentration: 10 μmol/L (for endothelial cells); 25, 50, 75, 100 μg/mL (for A549 cells)
Incubation Time: 24 h (endothelial cells); 24-48 h (A549 cells)
Result: Reduced apoptosis (19%) compared to ox-LDL group (23%) in endothelial cells.
In A549 cells, increased sub-G1 population in a dose- and time-dependent manner, with 20.32% apoptotic cells at 75 μg/mL for 48 h.
In Vivo

Trilinolein (50, 100, 200 mg/kg; oral; single dose; 1 hour before ischemia, 24 hours after reperfusion) can reduce cerebral infarction area, neurological deficits and TUNEL-positive neuronal apoptosis in the Sprague-Dawley rat model of cerebral ischemia-reperfusion[3].
Trilinolein (100, 200 mg/kg; oral; once a day; 28 days) can reduce the intima/media ratio and PCNA-positive cells in the carotid artery ligation-induced intimal hyperplasia model of ICR mice, and reduce intimal hyperplasia[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: Male ICR mice (22-25 g) with carotid artery ligation-induced intimal hyperplasia model (ligation of left common carotid artery)[3]
Dosage: 100, 200 mg/kg
Administration: Oral administration (gastric gavage), once daily, 28 days (starting from the second day after ligation)
Result: Significantly reduced the intima/media ratio and decreased the percentage of PCNA-positive cells, ameliorating intimal hyperplasia.
Essai clinique
Masse moléculaire

879.38

Formule

C57H98O6

CAS No.
Appearance

Liquid (Density: 0.9184 g/cm3)

Color

Colorless to light yellow

SMILES

CCCCC/C=C\C/C=C\CCCCCCCC(OCC(OC(CCCCCCC/C=C\C/C=C\CCCCC)=O)COC(CCCCCCC/C=C\C/C=C\CCCCC)=O)=O

Structure Classification
Initial Source
Livraison

Room temperature in continental US; may vary elsewhere.

Stockage

-20°C, sealed storage, away from moisture and light

*In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)

Solvant et solubilité
In Vitro: 

DMSO : 100 mg/mL (113.72 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

Preparing
Stock Solutions
Concentration Solvent Mass 1 mg 5 mg 10 mg
1 mM 1.1372 mL 5.6858 mL 11.3716 mL
5 mM 0.2274 mL 1.1372 mL 2.2743 mL
View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Select the appropriate dissolution method based on your experimental animal and administration route.

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

  • Protocol 1

    Add each solvent one by one:  10% DMSO    40% PEG300    5% Tween-80    45% Saline

    Solubility: ≥ 2.5 mg/mL (2.84 mM); Clear solution

    This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

    Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

    Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
  • Protocol 2

    Add each solvent one by one:  10% DMSO    90% (20% SBE-β-CD in Saline)

    Solubility: ≥ 2.5 mg/mL (2.84 mM); Suspended solution

    This protocol yields a suspended solution of ≥ 2.5 mg/mL (saturation unknown). Suspended solution can be used for oral and intraperitoneal injection.

    Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

    Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Pureté et documentation
Références